ArticleTranslational andrology and urology2025
Machine learning based on automated 3D radiomics features to classify prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Determining accuracy of diagnosis and management of common presenting semen analyses using artificial intelligence programs.Translational andrology and urology · 2025Article
- Radiomics Reproducibility in Prostate Cancer Diagnosis Based on PROSTATEx.International neurourology journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: It can be difficult to decide clinically whether males with prostate-specific antigen (PSA) levels between 4 and 10 ng/mL should be suggested for a biopsy. This study aimed to develop a fully-automated magnetic resonance imaging (MRI) based prediction model for patients with PSA levels of 4-10 ng/mL to predict prostate cancer (PCa) preoperatively and reduce unnecessary biopsies. Methods: A retrospective study of 574 patients with PSA of 4-10 ng/mL was conducted, split into training (n=434) and testing (n=108) groups. A no-new-Net (nnU-net) model was trained for three-dimensional (3D) prostate segmentation on T2-weighted fast spin echo (T2FSE) MRI sequences and 1,595 radiomics features were extracted with PyRadiomics. There were 113 machine learning approaches compared to construct a radiomics model after features selection. The diagnostic performance of the model was compared with PSA and PSA density (PSAD). Results: The nnU-net model achieved relatively higher accuracy of segmentation for the prostate region in various datasets. The average dice was 95.33%, the average relative volume error (RVE) was 1.57%, and the average 95% Hausdorff distance (HD95) value was 2.73 mm. The radiomics model [area under the curve (AUC): 0.938; 95% confidence interval (CI): 0.916-0.960] shows superior accuracy to PSA (AUC: 0.542; 95% CI: 0.474-0.611) and PSAD (AUC: 0.718; 95% CI: 0.659-0.777) in predicting PCa (P<0.05). Conclusions: The automated 3D radiomics model holds the potential to reduce unnecessary biopsies and aid urologists in managing patients with PSA levels of 4-10 ng/mL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.